Targeted therapies in gynecologic cancers and melanoma

Seminars in Diagnostic Pathology

Volumn 25, Issue 4, 2008, Pages 262-273

  Ortega, Eugenia ^a   Marti, Rosa M ^a   Yeramian, Andree ^a   Sorolla, Anabel ^a   Dolcet, Xavier ^a   Llobet, David ^a   Abal, Leandro ^a   Santacana, Maria ^a   Pallares, Judit ^a   Llombart Cussac, Antonio ^a   Matias Guiu, Xavier ^a  

^a HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

Author keywords

Endometrial carcinoma; Melanoma; Ovarian carcinoma; Target therapies

Indexed keywords

5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; AP 23573; AXITINIB; AZD 0325901; BEVACIZUMAB; BORTEZOMIB; CARBOPLATIN; CETUXIMAB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DACARBAZINE; DOCETAXEL; ERLOTINIB; EVEROLIMUS; FULVESTRANT; GEFITINIB; GEMCITABINE; IMATINIB; IRINOTECAN; LAPATINIB; MEDROXYPROGESTERONE ACETATE; N (2,3 DIHYDROXYPROPOXY) 3,4 DIFLUORO 2 (2 FLUORO 4 IODOANILINO)BENZAMIDE; OBLIMERSEN; PACLITAXEL; PERTUZUMAB; SORAFENIB; SUNITINIB; TEMSIROLIMUS; TRASTUZUMAB; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB;

ADVANCED CANCER; ALLELIC DELETION; ANTIANGIOGENIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER RESISTANCE; CANCER SURVIVAL; CELL ACTIVATION; CELL CYCLE; CELL CYCLE REGULATION; CHROMOSOME; CLIMACTERIUM; CLINICAL FEATURE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG TARGETING; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GENE LOCUS; GENE MUTATION; GENE TARGETING; GENETIC SUSCEPTIBILITY; HUMAN; MELANOMA; MONOTHERAPY; NONHUMAN; ONCOGENE NEU; ONCOGENE RAS; OVARY CARCINOMA; PATHOLOGY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; UVEA MELANOMA;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; FEMALE; GENITAL NEOPLASMS, FEMALE; HUMANS; MELANOMA;

EID: 53749100556     PISSN: 07402570     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.semdp.2008.07.008     Document Type: Article

References (66)

1. Moreno-Bueno G., Sánchez-Estévez C., Cassia R., et al. Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas. Cancer Res 63 (2003) 5697-5702
2. Bockman J.V. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 15 (1983) 10-17
3. Lax S.F., and Kurman R.J. A dualistic model for endometrial carcinogenesis based on immunohistochemical and molecular genetic analyses. Verh Dtsch Ges Pathol 81 (1997) 228-232
4. Matias-Guiu X., Catasus L., Bussaglia E., et al. Molecular pathology of endometrial hyperplasia and carcinoma. Hum Pathol 32 (2001) 569-577
5. Catasús L., Machin P., Matias-Guiu X., et al. Microsatellite instability in endometrial carcinomas clinicopathologic correlations in a series of 42 cases. Human Pathol 29 (1998) 1160-1164
6. Bussaglia E., del Rio E., Matias-Guiu X., et al. PTEN mutations in endometrial carcinomas. A molecular and clinicopathologic analysis of 38 cases. Hum Pathol 31 (2000) 312-317
7. Velasco A., Bussaglia E., Pallares J., et al. PIK3CA gene mutations in endometrial carcinoma: correlation with PTEN and K-RAS alterations. Hum Pathol 37 (2006) 1465-1472
8. Machin P., Catasus L., Pons C., et al. CTNNB1 mutations and beta-catenin expression in endometrial carcinomas. Hum Pathol 33 (2002) 206-212
9. Moreno-Bueno G., Hardisson D., Sánchez C., et al. Abnormalities of the APC/beta-catenin pathway in endometrial cancer. Oncogene 21 (2002) 7981-7990
10. Tashiro H., Isacson C., Levine R., et al. p53 gene mutations are common in uterine serous carcinoma and occurs early in their pathogenesis. Am J Pathol 150 (1997) 177-185
11. Sherman M.E., Bur M.E., and Kurman R.J. p53 in endometrial cancer and its putative precursors: evidence for diverse pathways of tumorigenesis. Hum Pathol 26 (1995) 1268-1274
12. Mutter G.L., Lin M.C., Fitzgerald J.T., et al. Altered PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 92 (2000) 924-931
13. Levine R.L., Cargile C.B., Blazes M.S., et al. PTEN mutations and microsatellite instability in complex atypical hyperplasia, a precursor lesion to uterine endometrioid carcinoma. Cancer Res 58 (1998) 3254-3258
14. Oda K., Stokoe D., Taketani Y., et al. High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65 (2005) 10669-10673
15. Gagnon V., St-Germain M.E., Parent S., et al. Akt activity in endometrial cancer cells: regulation of cell survival through cIAP-1. Int J Oncol 23 (2003) 803-810
16. Chon H.S., Hu W., and Kavanagh J.J. Targeted therapies in gynecologic cancers. Curr Cancer Drug Targets 6 (2006) 333-363
17. Podsypanina K., Lee R.T., Politis C., et al. An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice. Proc Natl Acad Sci U S A 98 (2001) 10320-10325
18. Khalifa M.A., Abdoh A.A., Mannel R.S., et al. Prognostic utility of epidermal growth factor receptor overexpression in endometrial adenocarcinoma. Cancer 73 (1994) 370-376
19. Morrison C., Zanagnolo V., Ramirez N., et al. HER-2 is an independent prognostic factor in endometrial cancer: association with outcome in a large cohort of surgically staged patients. J Clin Oncol 24 (2006) 2376-2385
20. Pallares J., Martinez-Guitarte J.L., Dolcet X., et al. Abnormalities in NF-kB family and related proteins in endometrial carcinoma. A tissue microarray study. J Pathol 13 (2004) 569-577
21. Catasús L., Matias-Guiu X., Machin P., et al. BAX somatic frameshift mutations in endometrioid adenocarcinomas of the endometrium: evidence for a tumor progression role in endometrial carcinomas with microsatellite instability. Lab Invest 78 (1998) 1439-1444
22. Dolcet X., Llobet D., Encinas M., et al. Proteasome inhibitors induce death but activate NF-kappaB on endometrial carcinoma cell lines and primary culture explants. J Biol Chem 281 (2006) 22118-22130
23. Llobet D., Eritja N., Encinas M., et al. Antioxidants block proteasome inhibitor function in endometrial carcinoma cells. Anticancer Drugs 19 (2008) 115-124
24. Dolcet X., Llobet D., Pallares J., et al. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest 85 (2005) 885-894
25. Llobet D., Eritja N., Encinas M., et al. CK2 controls TRAIL and Fas sensitivity by regulating FLIP levels in endometrial carcinoma cells. Oncogene 27 (2008) 2513-2524
26. Gunin A.G., Kapitova I.N., and Suslonova N.V. Effects of histone deacetylase inhibitors on estradiol-induced proliferation and hyperplasia formation in the mouse uterus. J Endocrinol 185 (2005) 539-549
27. Takai N., Desmond J.C., Kumagai T., et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin Cancer Res 10 (2004) 1141-1149
28. Matias-Guiu X., and Prat J. Molecular pathology of ovarian carcinomas. Virchows Arch 433 (1998) 103-111
29. Kurman R.J., and Shih IeM. Pathogenesis of ovarian cancer: lessons from morphology and molecular biology and their clinical implications. Int J Gynecol Pathol 27 (2008) 151-160
30. Esteller M., Silva J.M., Dominguez G., et al. Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. J Natl Cancer Inst 92 (2000) 564-569
31. Gras E., Cortes J., Diez O., et al. Loss of heterozygosity on chromosome 13q12-q14, BRCA-2 mutations and lack of BRCA-2 promoter hypermethylation in sporadic epithelial ovarian tumors. Cancer 92 (2001) 787-795
32. Gras E., Catasus L., Argüelles R., et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer 92 (2001) 2829-2836
33. Tsuchiya A., Sakamoto M., Yasuda J., et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am J Pathol 163 (2003) 2503-2512
34. Cuatrecasas M., Villanueva A., Matias-Guiu X., et al. K-ras mutations in mucinous ovarian tumors: a clinicopathologic and molecular study of 95 cases. Cancer 79 (1997) 1581-1586
35. Burger R.A., Sill M., Monk B.J., et al. Phase II trial of bevacizumab in persisntent or recurrent epithelail ovarian cancer or primary peritoneal cancer. A Gynecologic Oncology Group study (abstract). J Clin Oncol 23 (2005) 457s
36. Palayekar M.J., and Herzog T.J. The emerging role of epidermal growth factor receptor inhibitors in ovarian cancer. Int J Gynecol Cancer (2007) Dec 5 [Epub ahead of print]
37. Bookman M.A., Darcy K.M., Clarke-Pearson D., et al. Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. J Clin Oncol 21 (2003) 283-290
38. Gordon M.S., Matei D., Aghajanian C., et al. Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. J Clin Oncol 24 (2006) 4324-4332
39. Dharap S.S., Chandna P., Wang Y., et al. Molecular targeting of BCL2 and BCLXL proteins by synthetic BCL2 homology 3 domain peptide enhances the efficacy of chemotherapy. J Pharmacol Exp Ther 316 (2006) 992-998
40. Mross K., Steinbild S., Baas F., et al. Results from an in vitro and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib. Eur J Cancer 43 (2007) 55-63
41. Hussein M.R. Genetic pathways to melanoma tumorogenesis. J Clin Pathol 57 (2004) 797-801
42. Newton Bishop J.A., and Gruis N.A. Genetics: what advice for patients who present with a family history of melanoma?. Semin Oncol 34 (2007) 452-459
43. Curtin J.A., Fridlyand J., Tageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005) 2135-2147
44. Curtin J.A., Busam K., Pinkel D., et al. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol 24 (2006) 4340-4346
45. Thompson J.F., Scolyer R.A., and Kefford R.F. Cutaneous melanoma. Lancet 365 (2005) 687-701
46. Lorigan P., Eisen T., and Hauschild A. Systemic therapy for metastatic malignant melanoma-from deeply disappointing to bright future?. Exp Dermatol 17 (2008) 383-394
47. Fecher L.A., Amaravadi R.K., and Flaherty K.T. The MAPK pathway in melanoma. Curr Opin Oncol 20 (2008) 183-189
48. Gray Shopfer V.C., da Rocha Dias S., and Marais R. The role of B-RAF in melanoma. Cancer Metastasis Rev 24 (2005) 165-183
49. Panka D.J., Wang W., Atkins M.B., et al. The Raf inhibitor BAY 43-9006 (Sorafenib) induces caspase-independent apoptosis in melanoma cells. Cancer Res 66 (2006) 1611-1619
50. Eisen T., Ahmad T., Flahery K.T., et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br J Cancer 95 (2006) 581-586
51. McDermott D.F., Sosman J.A., Gonzalez R., et al. Double-blind randomized phase II study of the combination of sorafenib and dacarbazine in patients with advanced melanoma: a report from the 11715 Study Group. J Clin Oncol 26 (2008) 2178-2185
52. Abi-Habib R.J., Urieto J.O., Liu S., et al. BRAF status and mitogen-activated protein/extracellular signal-regulated kinase kinase 1/2 activity indicate sensitivity of melanoma cells to anthrax lethal toxin. Mol Cancer Ther 4 (2005) 1303-1310
53. Robertson G.P. Functional and therapeutic significance of Akt deregulation in malignant melanoma. Cancer Metastasis Rev 24 (2005) 273-285
54. Chan S. Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer. Br J Cancer 91 (2004) 1420-1424
55. Mayorga M.E., Sanchis D., Perez de Santos A.M., et al. Antiproliferative effect of STI571 on cultured human cutaneous melanoma-derived cell lines. Melanoma Res 16 (2006) 127-135
56. Grossman D. Imatinib mesylate for melanoma: will a new target be revealed?. J Invest Dermatol 123 (2004) xi-xiii
57. Lefevre G., Glotin A.L., Calipel A., et al. Roles of stem cell factor/c-kit and effects of Glivec(R)/STI571 in human uveal melanoma cell tumorigenesis. J Biol Chem 23 (2004) 31769-31779
58. Amiri K.I., Horton L.W., LaFleur B.J., et al. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE. PS-341) as a therapeutic agent for malignant melanoma. Cancer Res 64 (2004) 4912-4918
59. Sorolla A., Yeramian A., Dolcet X., et al. Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br J Dermatol 158 (2008) 496-504
60. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
61. Moreira J.N., Santos A., and Simões S. Bcl-2-targeted antisense therapy (Oblimersen sodium): towards clinical reality. Rev Recent Clin Trials 1 (2006) 217-235
62. Tarhini A.A., and Kirkwood J.M. Oblimersen in the treatment of metastatic melanoma. Future Oncol 3 (2007) 263-271
63. Varker K.A., Biber J.E., Kefauver C., et al. A randomized phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma. Ann Surg Oncol 14 (2007) 2367-2376
64. Tarhini A.A., and Kirkwood J.M. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer. Curr Opin Mol Ther 9 (2007) 505-514
65. Lens M., Ferrucci P.F., and Testori A. Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: recent findings. Recent Patents Anticancer Drug Discov 3 (2008) 105-113
66. Marti R.M., Mayorga M.E., Llecha N., et al. Expression of somatostatin receptors (SSTR) in melanoma cell lines. Effect of somatostatin analogues on their proliferation. Arch Dermatol Res 299 (2007) 290